Comparison · NCT01924533-9e3ad3ea
Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2 vs Placebo Tablets bd + Paclitaxel 80 mg/m^2: Progression-Free Survival (PFS)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2 vs Placebo Tablets bd + Paclitaxel 80 mg/m^2: Progression-Free Survival (PFS). Trial comparisons, record NCT01924533-9e3ad3ea. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01924533-9e3ad3ea
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.179 | 0.137 | 0.23 | wilson | |
| Risk in group 2 | 0.111 | 0.0782 | 0.154 | wilson | |
| Risk difference, group 1 minus group 2 | 0.068 | 0.00766 | 0.128 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.61 | 1.05 | 2.48 | log | |
| Odds ratio, group 1 over group 2 | 1.75 | 1.06 | 2.88 | log | |
| Number needed to treat, for one more participant with the outcome on Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2 than on Placebo Tablets bd + Paclitaxel 80 mg/m^2 | 14.7 | 7.79 | 131 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2 | Olaparib 100 mg tablets bd + Paclitaxel 80 mg/m\^2 | 47 | 263 | OG000 |
| Group 2 | Placebo Tablets bd + Paclitaxel 80 mg/m^2 | Placebo tablets bd + Paclitaxel 80 mg/m\^2 | 29 | 262 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Progression-Free Survival (PFS)
- Description
Time from randomization until the date of objective radiological disease progression according to RECIST (v1.1) or death by any cause in the absence of progression. Objective progression is defined as at least a 20% increase in the sum of the diameters of the target lesions (compared to previous minimum sum) or an overall non-target lesion assessment of progression or a new lesion.
- Time frame
- Scans taken at baseline and then follow up assessments taken every 8 weeks up to Week 40 and then every 16 weeks until objective disease progression as defined by RECIST 1.1, assessed up to 3 years
- Population
- FAS analysis set population
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.
- NCT number
- NCT01924533
- Phases
- PHASE3
- Conditions
- Gastric Cancer
- Interventions
- Olaparib, Paclitaxel, Placebo
- Lead sponsor
- AstraZeneca
- Results first posted
- 2018-11-07
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01924533?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01924533-9e3ad3ea